Article révisé par les pairs
Titre:
  • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Auteur:Gianni, Luca; Dafni, Urania; Gelber, Richard; de Azambuja, Evandro; Muehlbauer, Susanne; Goldhirsch, Aron; Untch, Michael; Smith, Ian; Baselga, José; Jackisch, Christian; Cameron, David A; Mano, Max S.; Pedrini, José Luiz; Veronesi, Andrea; Mendiola, Cesar; Pluzanska, Anna; Semiglazov, Vladimir; Vrdoljak, Eduard; Eckart, Michael J; Shen, Zhenzhou; Skiadopoulos, George; Procter, Marion; Pritchard, Kathleen; Piccart-Gebhart, Martine; Bell, Richard H; Herceptin Adjuvant (HERA) Trial Study Team,
Informations sur la publication:Lancet oncology, 12, 3, page (236-244)
Statut de publication:Publié, 2011-03
Sujet CREF:Cancérologie
MeSH keywords:Adult
Antibodies, Monoclonal -- therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- pathology -- therapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Middle Aged
Randomized Controlled Trials as Topic
Receptor, erbB-2
Survival Analysis
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(11)70033-X
info:pii/S1470-2045(11)70033-X
info:scp/79952041937
info:pmid/21354370

Documents en relation

DI-fusion